Compare Biogen Inc (BIIB) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs PPG Industries, Inc. — how do they compare? Biogen Inc trades at $206.74 (market cap $30.13B), while PPG Industries, Inc. trades at $115.2 (market cap $25.82B). The key difference: Biogen Inc is the larger of the two by market cap, and PPG Industries, Inc. pays a 2.55% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PPG | |
|---|---|---|
Market Cap | $30.13B | $25.82B |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $131.56 |
52-Week Low | $128.93 | $94.34 |
Enterprise Value | $37.20B | $31.69B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
PPG Industries trades at $115.47, down 3.55% amid bearish technical signals, though fundamentals show resilience with Q2 2026 sales up 7% year-over-year and a 4.2% dividend hike in July 2026. The stock's valuation appears reasonable with a P/E of 16.67 and P/S of 1.59, while profitability metrics like a 9.57% net margin and 19.63% ROE support operational strength. Recent leadership changes in Industrial Coatings and FTSE4Good recognition highlight ongoing corporate developments.
Wall Street maintains a bullish stance with 55% buy ratings and a $129.17 consensus target, implying 12% upside, but near-term risks include raw material cost pressures and mixed earnings performance. The technical bearish signal and proximity to support at $114 suggest cautious entry points, while the dividend aristocrat status and solid cash flow provide downside protection for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
